ALLOGENE THERAPEUTICS, INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
R&D↓-36.3% -$16M
$29M
D&A↓-5.4% -$176K
$3M
Operating Income↑+37.4% +$27M
$-45M
EBITDA↓-5.4% -$176K
$3M
Interest Expense↑+286.4% +$232K
$313K
Other Income/Expense
—
Pretax Income
—
Tax Provision↓-100.0% -$443K
$0
Net Income↑+37.5% +$25M
$-41M
Operating Margin
-315927.3%
Net Margin
-295454.5%
Effective Tax Rate
—
ETR (Continuing Operations)↑+0.2pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
Operating Lease Cost↓-6.7% -$170K
$2M
Revenue YoY Variation↓-73.3pts
-100.0%
Income YoY Variation↑+51.4pts
37.4%
Revenue QoQ Variation
-100.0%
Income QoQ Variation↑+21.5pts
21.0%